Welcome to Markets Desk, your midday read on the stories moving money and markets.
The Nasdaq-one hundred is deep in correction territory for the third time this year, as mounting anxiety over artificial intelligence valuations continues to drag on the tech sector. What started as an October pullback has investors asking whether this repricing has further to run, or whether it tips into bear market territory.
Shifting from equities to geopolitics, U.S. forces have struck Iran's Qeshm Island in what marks a significant escalation, even as President Trump publicly played down the prospect of broader conflict following Tuesday's midterm elections. Markets are watching energy prices closely, as any sustained tension in the Persian Gulf carries direct implications for oil supply and risk appetite globally.
On a brighter note for the pharmaceutical space, Eli Lilly closed last Thursday at one thousand four hundred seventeen dollars and fifty four cents, up more than ten percent on the week, after a blowout earnings report powered by surging demand for its GLP-one drugs Mounjaro and Zepbound. The company's market value now sits above one point three three trillion dollars, approaching record highs as the weight-loss drug cycle shows no signs of cooling.
That's the tape. Markets Desk, signing off the floor.
